The Motley Fool

Covid-19 drug maker’s share price triples! Here’s what I’m doing now

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

globe with a mask and text coronavirus
Image source: Getty Images

The share price of 4D pharma (LSE: DDDD) is on a tear as I write. It’s up a whole 197% from its lowest point in late March. This is a sharp rise by any standards. And for good reason.

It received a go ahead for the next phase of its Covid-19 treatment a few days ago.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Long-term potential

Promising as this sounds, as a long-term investor I’d like to take a closer look at DDDD to understand its potential prospects. It was founded in 2014, and has been listed on AIM since. It’s pre-revenue right now and is researching a line of treatment called ‘live biotherapeutics’. This treatment focuses on gut bacteria to find cures for a range of diseases. I reckon it could be a while before these cures become successful revenue generators for 4D pharma.

The challenging Covid-19 fight

It’s also entirely likely that some treatments may not be immediately successful, especially when it comes to Covid-19. Take for instance, the case of Remdesivir, a Covid-19 drug produced by US-based company Gilead Sciences, which hasn’t been effective in its first clinical trials. Or consider France’s Sanofi’s rheumatoid arthritis drug, which can be used in only the most affected Covid-19 patients. It was earlier believed to be a potential cure for a broader set of those infected according to a Reuters report. The key point here is that it could be a while before we’d see the fruits of 4D pharma’s labour show up in its financials. 

If I’m truly convinced of investing in companies that are in the trenches in the fight against coronavirus, I’d consider a different approach. I’d donate to medical research if the cause calls out to me. There’s much research underway to provide better treatments for critical illnesses. But that’s not investment, and shouldn’t be seen as such.

My goal as an investor is to try my best to ensure returns. For this reason, I’m most inclined to invest in those companies that already have a proven track record.

Considering FTSE 100 alternatives

FTSE 100 pharma biggies are my bet for the long-term as a result. Consider the example of GlaxoSmithkline,  which has also recently been in the news for working on a coronavirus vaccine. This incidentally, is also a collaboration with Sanofi, which, as I pointed out earlier is already providing treatment in critical Covid-19 cases. It’s expected to be available only in the second half of 2021. 

Or AstraZeneca, which is working on a coronavirus treatment as well. Of course, it will be some time before we know the results of these endeavours. But these are already established companies. They are well-diversified and are financially sound. Moreover, they are likely to come out quite unscathed by the coronavirus crisis, and indeed the stock market crash. I think they are better investments for now. 

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.